An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
复制标题
DOI：
10.1016/j.jacl.2013.10.001
复制
发表时间：
2013-12-01
影响因子：
4.4
通讯作者：
Zhao, Dong
中科院分区：
文献类型：
--
作者：
Grundy, Scott M.;Arai, Hidenori;Zhao, Dong
国际动脉粥样硬化学会的一个国际小组制定了一套新的血脂异常管理建议。该小组确定非高密度脂蛋白胆固醇(非高密度脂蛋白-C)是主要的致动脉粥样硬化的脂蛋白。一级预防和二级预防分开考虑。对于这两种形式的预防，得出了导致动脉粥样硬化的脂蛋白的最佳水平。对于一级预防，建议强调生活方式疗法以减少致动脉粥样硬化的脂蛋白；药物疗法仅适用于高危对象。风险评估的基础是根据不同国家或地区基线人口风险的差异对终身风险进行估计。二级预防强调使用降胆固醇药物来达到致动脉粥样硬化的脂蛋白的最佳水平。由爱思唯尔公司代表国家脂质协会出版。
An international panel of the International Atherosclerosis Society has developed a new set of recommendations for management of dyslipidemia. The panel identifies non-high density lipoprotein cholesterol (non-HDL-C) as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for higher risk subjects. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins. Published by Elsevier Inc. on behalf of National Lipid Association.